STAAR Surgical Company (NASDAQ:STAA) finished Friday with an addition of $0.63 to close at $48.54, an upside of 1.31 percent. An average of 749,560 shares of common stock have been traded in the last five days. There was a fall of -$1.53 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 769,385 shares traded, while the 50-day average volume stands at 664,888.
STAA stock has decreased by -15.01% in the last month. The company shares reached their 1-month lowest point of $46.35 on 12/28/22. With the stock rallying to its 52-week high on 08/12/22, shares of the company touched a low of $46.35 and a high of $112.27 in 52 weeks. It has reached a new high 4 times so far this year and lost -46.83% or -$42.76 in price. In spite of this, the price is down -56.76% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
STAA stock investors should be aware that STAAR Surgical Company (STAA) stock had its last reported insider trading activity 95 days ago on Dec 29. In this transaction, the insider spent $2,656,875. Chief Technology Officer, Holliday Keith, disposed of 16,582 shares at a price of $106.29 on Aug 15. The insider now owns more than $1,762,498 worth of shares. Prior to that, President & CEO Mason Caren L went on to Sale 35,000 shares at $58.48 each on May 20. An amount of $2,046,800 was transacted.
STAAR Surgical Company (STAA) has a trailing price-to-earnings (P/E) ratio of 63.37. The stock’s beta is 1.03. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 8.67, the price-to-book (PB) ratio at 7.29, and the price-to-cash flow ratio at 108.09.
The quick ratio of STAAR Surgical Company for the three months ended June 29 was 6.10, and the current ratio was 6.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $178.64 million compared to revenue of $230.47 million.
For the three-month period that ended June 29, STAAR Surgical Company had $82.09 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $10.26 million in the quarter, while revenues were grew 41.33%. The analyst consensus anticipated STAAR Surgical Company’s latest quarter earnings to come in at $0.16 per share, but it turned out to be $0.26, a 62.50% surprise. For the quarter, EBITDA amounted to $14.48 million. Shareholders own equity worth $48.21 million.
From a technical analysis perspective, let’s take a brief look at STAAR Surgical Company (STAA) price momentum. RSI 9-day as of the close on 30 December was 33.09%, suggesting the stock is Neutral, with historical volatility in this time frame at 55.54%.
As of today, STAA’s price is $47.93 -3.06% or -$1.53 from its 5-day moving average. STAA is currently trading -17.91% lower than its 20-day SMA and -41.44% lower than its 100-day SMA. However, the stock’s current price level is -31.15% below the SMA50 and -28.12% below the SMA200.
The stochastic %K and %D were 7.67% and 6.23%, respectively, and the average true range (ATR) was 2.77. With the 14-day stochastic at 11.96% and the average true range at 3.00, the RSI (14) stands at 34.37%. The stock has reached -0.90 on the 9-day MACD Oscillator while the 14-day reading was at -4.29.
BTIG Research reiterated its a Buy rating on STAAR Surgical Company (NASDAQ: STAA), but raised their price target to $80, indicating a potential price increase of 39.32% for the stock. The consensus rating for STAAR Surgical Company (STAA) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell STAA, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 9 others rate it as a “buy”.
What is STAA’s price target for the next 12 months?
Analysts predict a range of price targets between $60.00 and $105.00, with a median target of $83.00. Taking a look at these predictions, the average price target given by analysts for STAAR Surgical Company (STAA) stock is $80.22.